{"transactions":[{"id":692760,"issuer":{"id":4564,"kind":"organization","name":"Braveheart Bio, Inc."},"owners":[{"id":25347,"kind":"person","name":"Rickey James Paul","position":1,"cik":"0001606243","reported_name":"Rickey James Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-07T20:41:40.000Z","date":"2026-08-05","kind":"grant","planned":false,"acquired":true,"shares":300000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/48th of the shares subject to such option vest and become exercisable in substantially equal monthly installments on each monthly anniversary of July 23, 2026, subject to the Reporting Person's continuous service to the Issuer on each such date."}],"balance_after":300000,"derivative":{"exercise_price":18,"expiration_date":"2036-08-04","underlying":"Common Stock","underlying_shares":300000},"source":{"system":"sec-edgar","filing":"0001470831-26-000804","document":"wk-form4_1786135298.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1606243/000147083126000804/wk-form4_1786135298.xml","form_type":"4"}},{"id":692759,"issuer":{"id":4564,"kind":"organization","name":"Braveheart Bio, Inc."},"owners":[{"id":25347,"kind":"person","name":"Rickey James Paul","position":1,"cik":"0001606243","reported_name":"Rickey James Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Financial Officer"}}],"security":"Common Stock","published_at":"2026-08-07T20:41:40.000Z","date":"2026-08-07","kind":"purchase","planned":false,"acquired":true,"shares":27777,"price":18,"value":499986.0,"ownership":{"direct":true},"balance_after":520927,"source":{"system":"sec-edgar","filing":"0001470831-26-000804","document":"wk-form4_1786135298.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1606243/000147083126000804/wk-form4_1786135298.xml","form_type":"4"}},{"id":1508561,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25347,"kind":"person","name":"Rickey James Paul","position":1,"cik":"0001606243","reported_name":"Rickey James Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to buy)","published_at":"2024-05-21T00:07:07.000Z","date":"2024-05-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":78000,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"(Continued from Footnote 7) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F12","text":"One-fourth (1/4th) of the Shares subject to the Option will vest on January 4, 2025, and one thirty-sixth (1/36th) of the remaining Shares subject to the Option shall vest each month thereafter, subject to the Reporting Person continuing to be a Service Provider through each such date."}],"balance_after":0,"derivative":{"exercise_price":18.33,"expiration_date":"2034-01-03","underlying":"Common Stock","underlying_shares":78000},"source":{"system":"sec-edgar","filing":"0001626199-24-000094","document":"wk-form4_1716250016.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1606243/000162619924000094/wk-form4_1716250016.xml","form_type":"4"}},{"id":1508560,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25347,"kind":"person","name":"Rickey James Paul","position":1,"cik":"0001606243","reported_name":"Rickey James Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to buy)","published_at":"2024-05-21T00:07:07.000Z","date":"2024-05-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":108999,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"(Continued from Footnote 7) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F11","text":"One-fourth (1/4th) of the Shares subject to the Option will vest on January 4, 2024, and one thirty-sixth (1/36th) of the remaining Shares subject to the Option shall vest each month thereafter, subject to the Reporting Person continuing to be a service provider through each such date."}],"balance_after":0,"derivative":{"exercise_price":7.55,"expiration_date":"2033-01-03","underlying":"Common Stock","underlying_shares":108999},"source":{"system":"sec-edgar","filing":"0001626199-24-000094","document":"wk-form4_1716250016.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1606243/000162619924000094/wk-form4_1716250016.xml","form_type":"4"}},{"id":1508559,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25347,"kind":"person","name":"Rickey James Paul","position":1,"cik":"0001606243","reported_name":"Rickey James Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to buy)","published_at":"2024-05-21T00:07:07.000Z","date":"2024-05-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":112500,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"(Continued from Footnote 7) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F10","text":"One-fourth (1/4) of the shares subject to the option will vest on January 4, 2023, and one thirty-sixth (1/36th) of the remaining shares subject to the option shall vest each month thereafter, subject to Reporting Person continuing to be a service provider through each such date."}],"balance_after":0,"derivative":{"exercise_price":13.3,"expiration_date":"2032-01-03","underlying":"Common Stock","underlying_shares":112500},"source":{"system":"sec-edgar","filing":"0001626199-24-000094","document":"wk-form4_1716250016.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1606243/000162619924000094/wk-form4_1716250016.xml","form_type":"4"}},{"id":1508558,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25347,"kind":"person","name":"Rickey James Paul","position":1,"cik":"0001606243","reported_name":"Rickey James Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to buy)","published_at":"2024-05-21T00:07:07.000Z","date":"2024-05-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":112945,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"(Continued from Footnote 7) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F9","text":"One-fourth (1/4th) of the Shares subject to the Option will vest on January 5, 2022, and one thirty-sixth (1/36th) of the remaining Shares subject to the Option shall vest each month thereafter, subject to the Reporting Person continuing to be a service provider through each such date."}],"balance_after":0,"derivative":{"exercise_price":13.2,"expiration_date":"2031-01-04","underlying":"Common Stock","underlying_shares":112945},"source":{"system":"sec-edgar","filing":"0001626199-24-000094","document":"wk-form4_1716250016.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1606243/000162619924000094/wk-form4_1716250016.xml","form_type":"4"}},{"id":1508557,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25347,"kind":"person","name":"Rickey James Paul","position":1,"cik":"0001606243","reported_name":"Rickey James Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to buy)","published_at":"2024-05-21T00:07:07.000Z","date":"2024-05-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":1214,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"(Continued from Footnote 7) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":3.23,"expiration_date":"2030-01-22","underlying":"Common Stock","underlying_shares":1214},"source":{"system":"sec-edgar","filing":"0001626199-24-000094","document":"wk-form4_1716250016.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1606243/000162619924000094/wk-form4_1716250016.xml","form_type":"4"}},{"id":1508556,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25347,"kind":"person","name":"Rickey James Paul","position":1,"cik":"0001606243","reported_name":"Rickey James Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to buy)","published_at":"2024-05-21T00:07:07.000Z","date":"2024-05-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":143,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"(Continued from Footnote 7) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":6.51,"expiration_date":"2029-02-05","underlying":"Common Stock","underlying_shares":143},"source":{"system":"sec-edgar","filing":"0001626199-24-000094","document":"wk-form4_1716250016.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1606243/000162619924000094/wk-form4_1716250016.xml","form_type":"4"}},{"id":1508555,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25347,"kind":"person","name":"Rickey James Paul","position":1,"cik":"0001606243","reported_name":"Rickey James Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to buy)","published_at":"2024-05-21T00:07:07.000Z","date":"2024-05-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":137,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"(Continued from Footnote 7) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":5.02,"expiration_date":"2027-04-11","underlying":"Common Stock","underlying_shares":137},"source":{"system":"sec-edgar","filing":"0001626199-24-000094","document":"wk-form4_1716250016.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1606243/000162619924000094/wk-form4_1716250016.xml","form_type":"4"}},{"id":1508554,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25347,"kind":"person","name":"Rickey James Paul","position":1,"cik":"0001606243","reported_name":"Rickey James Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to buy)","published_at":"2024-05-21T00:07:07.000Z","date":"2024-05-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":836,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F5","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"price","element":"transactionPricePerShare","label":"F7","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each option to purchase shares of Company Common Stock (a Company Option) that was then outstanding but not then vested or exercisable became immediately vested and exercisable in full. At the Effective Time, each Company Option that was then outstanding was automatically cancelled and, if such Company Option had a per share exercise price less than the Merger Consideration, the holder thereof became entitled to receive a cash payment, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the total number of shares of Company Common Stock underlying such Company Option by (ii) the excess of the Merger Consideration over the exercise price per share such Company Option."},{"field":"price","element":"transactionPricePerShare","label":"F8","text":"(Continued from Footnote 7) Any Company Option that had an exercise price per share that was equal to or exceeded the Merger Consideration was cancelled without any cash payment or other consideration being made in respect thereof."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The option to purchase shares of Company Common Stock (the Company Option) is fully vested and exercisable."}],"balance_after":0,"derivative":{"exercise_price":11.31,"expiration_date":"2028-01-01","underlying":"Common Stock","underlying_shares":836},"source":{"system":"sec-edgar","filing":"0001626199-24-000094","document":"wk-form4_1716250016.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1606243/000162619924000094/wk-form4_1716250016.xml","form_type":"4"}},{"id":1508553,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25347,"kind":"person","name":"Rickey James Paul","position":1,"cik":"0001606243","reported_name":"Rickey James Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-05-21T00:07:07.000Z","date":"2024-05-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":31200,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Includes 31,200 shares of common stock underlying a restricted stock unit grant made on January 4, 2024 (the RSUs). One-fourth (1/4th) of the RSUs will vest on January 1, 2025 and the remainder will vest in twelve (12) equal quarterly installments on April 1, 2025, July 1, 2025, October 1, 2025 and on January 1, April 1, July 1, and October 1 of each subsequent year until all RSUs are vested on January 1, 2028, subject to Participant continuing to be a Service Provider through each such date."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the Merger Agreement), dated April 10, 2024, among Alpine Immune Sciences, Inc., a Delaware corporation (the Company), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (Parent), and Adams Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (Merger Sub). Pursuant to the Merger Agreement, Merger Sub completed a tender offer for shares of the Companys Common Stock, par value $0.001 per share (Company Common Stock), effective May 18, 2024 (the Offer Closing), and thereafter merged with and into the Company (the Merger, and together with the Offer Closing, the Transactions), effective May 20, 2024 (the Effective Time), with the Company surviving the Merger as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 2) In connection with the consummation of the Transactions, each share of the Company Common Stock was either (x) purchased at the Offer Closing for $65.00 in cash per share (the Offer Price), without interest thereon and subject to any applicable tax withholding or (y) automatically converted in the Merger at the Effective Time into the right to receive the Offer Price in cash, without interest thereon (the Merger Consideration), subject to any applicable tax withholding."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"Pursuant to the Merger Agreement, as of immediately prior to the Effective Time, each restricted stock unit of the Company (a Company RSU) that was then outstanding but not then vested became immediately vested in full. At the Effective Time, each Company RSU was automatically cancelled and the holder thereof became entitled to receive an amount in cash, without interest thereon and subject to any applicable tax withholding, equal to the product obtained by multiplying (i) the number of shares of Common Stock underlying such Company RSU by (ii) the Merger Consideration."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001626199-24-000094","document":"wk-form4_1716250016.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1606243/000162619924000094/wk-form4_1716250016.xml","form_type":"4"}},{"id":1508552,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25347,"kind":"person","name":"Rickey James Paul","position":1,"cik":"0001606243","reported_name":"Rickey James Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-05-21T00:07:07.000Z","date":"2024-05-20","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":26761,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This Form 4 reports securities disposed of pursuant to the Agreement and Plan of Merger (the Merger Agreement), dated April 10, 2024, among Alpine Immune Sciences, Inc., a Delaware corporation (the Company), Vertex Pharmaceuticals Incorporated, a Massachusetts corporation (Parent), and Adams Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of the Parent (Merger Sub). Pursuant to the Merger Agreement, Merger Sub completed a tender offer for shares of the Companys Common Stock, par value $0.001 per share (Company Common Stock), effective May 18, 2024 (the Offer Closing), and thereafter merged with and into the Company (the Merger, and together with the Offer Closing, the Transactions), effective May 20, 2024 (the Effective Time), with the Company surviving the Merger as a wholly owned subsidiary of Parent."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"(Continued from Footnote 2) In connection with the consummation of the Transactions, each share of the Company Common Stock was either (x) purchased at the Offer Closing for $65.00 in cash per share (the Offer Price), without interest thereon and subject to any applicable tax withholding or (y) automatically converted in the Merger at the Effective Time into the right to receive the Offer Price in cash, without interest thereon (the Merger Consideration), subject to any applicable tax withholding."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 31,200 shares of common stock underlying a restricted stock unit grant made on January 4, 2024 (the RSUs). One-fourth (1/4th) of the RSUs will vest on January 1, 2025 and the remainder will vest in twelve (12) equal quarterly installments on April 1, 2025, July 1, 2025, October 1, 2025 and on January 1, April 1, July 1, and October 1 of each subsequent year until all RSUs are vested on January 1, 2028, subject to Participant continuing to be a Service Provider through each such date."}],"balance_after":31200,"source":{"system":"sec-edgar","filing":"0001626199-24-000094","document":"wk-form4_1716250016.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1606243/000162619924000094/wk-form4_1716250016.xml","form_type":"4"}},{"id":1521831,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25347,"kind":"person","name":"Rickey James Paul","position":1,"cik":"0001606243","reported_name":"Rickey James Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to buy)","published_at":"2024-05-10T01:13:07.000Z","date":"2024-05-07","kind":"exercise","planned":false,"acquired":false,"shares":398,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F8","text":"100% of shares underlying the option were fully vested as of April 1, 2021."}],"balance_after":137,"derivative":{"exercise_price":5.02,"expiration_date":"2027-04-11","underlying":"Common Stock","underlying_shares":398},"source":{"system":"sec-edgar","filing":"0001626199-24-000066","document":"wk-form4_1715303576.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":12,"url":"https://www.sec.gov/Archives/edgar/data/1606243/000162619924000066/wk-form4_1715303576.xml","form_type":"4"}},{"id":1521830,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25347,"kind":"person","name":"Rickey James Paul","position":1,"cik":"0001606243","reported_name":"Rickey James Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to buy)","published_at":"2024-05-10T01:13:07.000Z","date":"2024-05-07","kind":"exercise","planned":false,"acquired":false,"shares":18286,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F7","text":"100% of the shares underlying the option were fully vested as of January 23, 2024."}],"balance_after":1214,"derivative":{"exercise_price":3.23,"expiration_date":"2030-01-22","underlying":"Common Stock","underlying_shares":18286},"source":{"system":"sec-edgar","filing":"0001626199-24-000066","document":"wk-form4_1715303576.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":11,"url":"https://www.sec.gov/Archives/edgar/data/1606243/000162619924000066/wk-form4_1715303576.xml","form_type":"4"}},{"id":1521829,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25347,"kind":"person","name":"Rickey James Paul","position":1,"cik":"0001606243","reported_name":"Rickey James Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to buy)","published_at":"2024-05-10T01:13:07.000Z","date":"2024-05-07","kind":"exercise","planned":false,"acquired":false,"shares":164,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"100% of the shares underlying the option were fully vested as of January 2, 2022."}],"balance_after":836,"derivative":{"exercise_price":11.31,"expiration_date":"2028-01-01","underlying":"Common Stock","underlying_shares":164},"source":{"system":"sec-edgar","filing":"0001626199-24-000066","document":"wk-form4_1715303576.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1606243/000162619924000066/wk-form4_1715303576.xml","form_type":"4"}},{"id":1521828,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25347,"kind":"person","name":"Rickey James Paul","position":1,"cik":"0001606243","reported_name":"Rickey James Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to buy)","published_at":"2024-05-10T01:13:07.000Z","date":"2024-05-07","kind":"exercise","planned":false,"acquired":false,"shares":857,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"100% of the shares underlying the option were fully vested as of February 6, 2023."}],"balance_after":143,"derivative":{"exercise_price":6.51,"expiration_date":"2029-02-05","underlying":"Common Stock","underlying_shares":857},"source":{"system":"sec-edgar","filing":"0001626199-24-000066","document":"wk-form4_1715303576.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1606243/000162619924000066/wk-form4_1715303576.xml","form_type":"4"}},{"id":1521827,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25347,"kind":"person","name":"Rickey James Paul","position":1,"cik":"0001606243","reported_name":"Rickey James Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to buy)","published_at":"2024-05-10T01:13:07.000Z","date":"2024-05-07","kind":"exercise","planned":false,"acquired":false,"shares":7055,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"Twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of January 5, 2021 (the \"Vesting Commencement Date\") and one forty-eighth (1/48th) of the shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), subject to the Reporting Person continuing to be a Service Provider through each such date."}],"balance_after":112945,"derivative":{"exercise_price":13.2,"expiration_date":"2031-01-04","underlying":"Common Stock","underlying_shares":7055},"source":{"system":"sec-edgar","filing":"0001626199-24-000066","document":"wk-form4_1715303576.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1606243/000162619924000066/wk-form4_1715303576.xml","form_type":"4"}},{"id":1521826,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25347,"kind":"person","name":"Rickey James Paul","position":1,"cik":"0001606243","reported_name":"Rickey James Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to buy)","published_at":"2024-05-10T01:13:07.000Z","date":"2024-05-07","kind":"exercise","planned":false,"acquired":false,"shares":1,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One-fourth (1/4th) of the Shares subject to the Option will vest on January 4, 2024, and one thirty-sixth (1/36th) of the remaining Shares subject to the Option shall vest each month thereafter, subject to the Reporting Person continuing to be a service provider through each such date."}],"balance_after":108999,"derivative":{"exercise_price":7.55,"expiration_date":"2033-01-03","underlying":"Common Stock","underlying_shares":1},"source":{"system":"sec-edgar","filing":"0001626199-24-000066","document":"wk-form4_1715303576.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1606243/000162619924000066/wk-form4_1715303576.xml","form_type":"4"}},{"id":1521825,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25347,"kind":"person","name":"Rickey James Paul","position":1,"cik":"0001606243","reported_name":"Rickey James Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-05-10T01:13:07.000Z","date":"2024-05-07","kind":"exercise","planned":false,"acquired":true,"shares":398,"price":5.02,"value":1997.96,"ownership":{"direct":true},"balance_after":57961,"source":{"system":"sec-edgar","filing":"0001626199-24-000066","document":"wk-form4_1715303576.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1606243/000162619924000066/wk-form4_1715303576.xml","form_type":"4"}},{"id":1521824,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25347,"kind":"person","name":"Rickey James Paul","position":1,"cik":"0001606243","reported_name":"Rickey James Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-05-10T01:13:07.000Z","date":"2024-05-07","kind":"exercise","planned":false,"acquired":true,"shares":18286,"price":3.23,"value":59063.78,"ownership":{"direct":true},"balance_after":57563,"source":{"system":"sec-edgar","filing":"0001626199-24-000066","document":"wk-form4_1715303576.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1606243/000162619924000066/wk-form4_1715303576.xml","form_type":"4"}},{"id":1521823,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25347,"kind":"person","name":"Rickey James Paul","position":1,"cik":"0001606243","reported_name":"Rickey James Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-05-10T01:13:07.000Z","date":"2024-05-07","kind":"exercise","planned":false,"acquired":true,"shares":164,"price":11.31,"value":1854.84,"ownership":{"direct":true},"balance_after":39277,"source":{"system":"sec-edgar","filing":"0001626199-24-000066","document":"wk-form4_1715303576.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1606243/000162619924000066/wk-form4_1715303576.xml","form_type":"4"}},{"id":1521822,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25347,"kind":"person","name":"Rickey James Paul","position":1,"cik":"0001606243","reported_name":"Rickey James Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-05-10T01:13:07.000Z","date":"2024-05-07","kind":"exercise","planned":false,"acquired":true,"shares":857,"price":6.51,"value":5579.07,"ownership":{"direct":true},"balance_after":39113,"source":{"system":"sec-edgar","filing":"0001626199-24-000066","document":"wk-form4_1715303576.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1606243/000162619924000066/wk-form4_1715303576.xml","form_type":"4"}},{"id":1521821,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25347,"kind":"person","name":"Rickey James Paul","position":1,"cik":"0001606243","reported_name":"Rickey James Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-05-10T01:13:07.000Z","date":"2024-05-07","kind":"exercise","planned":false,"acquired":true,"shares":7055,"price":13.2,"value":93126.0,"ownership":{"direct":true},"balance_after":38256,"source":{"system":"sec-edgar","filing":"0001626199-24-000066","document":"wk-form4_1715303576.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1606243/000162619924000066/wk-form4_1715303576.xml","form_type":"4"}},{"id":1521820,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25347,"kind":"person","name":"Rickey James Paul","position":1,"cik":"0001606243","reported_name":"Rickey James Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-05-10T01:13:07.000Z","date":"2024-05-07","kind":"exercise","planned":false,"acquired":true,"shares":1,"price":7.55,"value":7.55,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Includes 31,200 shares of common stock underlying a restricted stock unit grant made on January 4, 2024."}],"balance_after":31201,"source":{"system":"sec-edgar","filing":"0001626199-24-000066","document":"wk-form4_1715303576.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1606243/000162619924000066/wk-form4_1715303576.xml","form_type":"4"}},{"id":1667926,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25347,"kind":"person","name":"Rickey James Paul","position":1,"cik":"0001606243","reported_name":"Rickey James Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to buy)","published_at":"2024-01-30T00:04:16.000Z","date":"2024-01-26","kind":"exercise","planned":true,"acquired":false,"shares":44000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction reported in this Form 4 were effected pursuant to Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"100% of the shares underlying the option were fully vested as of January 2, 2022."}],"balance_after":1000,"derivative":{"exercise_price":11.31,"expiration_date":"2028-01-01","underlying":"Common Stock","underlying_shares":44000},"source":{"system":"sec-edgar","filing":"0001626199-24-000027","document":"wk-form4_1706573047.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1606243/000162619924000027/wk-form4_1706573047.xml","form_type":"4"}},{"id":1667925,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25347,"kind":"person","name":"Rickey James Paul","position":1,"cik":"0001606243","reported_name":"Rickey James Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to buy)","published_at":"2024-01-30T00:04:16.000Z","date":"2024-01-26","kind":"exercise","planned":true,"acquired":false,"shares":73764,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction reported in this Form 4 were effected pursuant to Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"100% of the shares underlying the option were fully vested as of February 6, 2023."}],"balance_after":1000,"derivative":{"exercise_price":6.51,"expiration_date":"2029-02-05","underlying":"Common Stock","underlying_shares":73764},"source":{"system":"sec-edgar","filing":"0001626199-24-000027","document":"wk-form4_1706573047.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1606243/000162619924000027/wk-form4_1706573047.xml","form_type":"4"}},{"id":1667924,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25347,"kind":"person","name":"Rickey James Paul","position":1,"cik":"0001606243","reported_name":"Rickey James Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to buy)","published_at":"2024-01-30T00:04:16.000Z","date":"2024-01-25","kind":"exercise","planned":true,"acquired":false,"shares":236,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction reported in this Form 4 were effected pursuant to Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"100% of the shares underlying the option were fully vested as of February 6, 2023."}],"balance_after":74764,"derivative":{"exercise_price":6.51,"expiration_date":"2029-02-05","underlying":"Common Stock","underlying_shares":236},"source":{"system":"sec-edgar","filing":"0001626199-24-000027","document":"wk-form4_1706573047.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1606243/000162619924000027/wk-form4_1706573047.xml","form_type":"4"}},{"id":1667923,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25347,"kind":"person","name":"Rickey James Paul","position":1,"cik":"0001606243","reported_name":"Rickey James Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-01-30T00:04:16.000Z","date":"2024-01-26","kind":"sale","planned":true,"acquired":false,"shares":44000,"price":25,"value":1100000.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction reported in this Form 4 were effected pursuant to Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2023."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001626199-24-000027","document":"wk-form4_1706573047.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1606243/000162619924000027/wk-form4_1706573047.xml","form_type":"4"}},{"id":1667922,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25347,"kind":"person","name":"Rickey James Paul","position":1,"cik":"0001606243","reported_name":"Rickey James Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-01-30T00:04:16.000Z","date":"2024-01-26","kind":"exercise","planned":true,"acquired":true,"shares":44000,"price":11.31,"value":497640.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction reported in this Form 4 were effected pursuant to Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2023."}],"balance_after":44000,"source":{"system":"sec-edgar","filing":"0001626199-24-000027","document":"wk-form4_1706573047.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1606243/000162619924000027/wk-form4_1706573047.xml","form_type":"4"}},{"id":1667921,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25347,"kind":"person","name":"Rickey James Paul","position":1,"cik":"0001606243","reported_name":"Rickey James Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-01-30T00:04:16.000Z","date":"2024-01-26","kind":"sale","planned":true,"acquired":false,"shares":73764,"price":22.3121,"value":1645829.7444,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction reported in this Form 4 were effected pursuant to Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $22.00 to $22.90. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001626199-24-000027","document":"wk-form4_1706573047.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1606243/000162619924000027/wk-form4_1706573047.xml","form_type":"4"}},{"id":1667920,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25347,"kind":"person","name":"Rickey James Paul","position":1,"cik":"0001606243","reported_name":"Rickey James Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-01-30T00:04:16.000Z","date":"2024-01-26","kind":"exercise","planned":true,"acquired":true,"shares":73764,"price":6.51,"value":480203.64,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction reported in this Form 4 were effected pursuant to Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2023."}],"balance_after":73764,"source":{"system":"sec-edgar","filing":"0001626199-24-000027","document":"wk-form4_1706573047.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1606243/000162619924000027/wk-form4_1706573047.xml","form_type":"4"}},{"id":1667919,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25347,"kind":"person","name":"Rickey James Paul","position":1,"cik":"0001606243","reported_name":"Rickey James Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-01-30T00:04:16.000Z","date":"2024-01-25","kind":"sale","planned":true,"acquired":false,"shares":236,"price":22,"value":5192.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction reported in this Form 4 were effected pursuant to Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2023."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001626199-24-000027","document":"wk-form4_1706573047.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1606243/000162619924000027/wk-form4_1706573047.xml","form_type":"4"}},{"id":1667918,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25347,"kind":"person","name":"Rickey James Paul","position":1,"cik":"0001606243","reported_name":"Rickey James Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-01-30T00:04:16.000Z","date":"2024-01-25","kind":"exercise","planned":true,"acquired":true,"shares":236,"price":6.51,"value":1536.36,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This transaction reported in this Form 4 were effected pursuant to Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2023."}],"balance_after":236,"source":{"system":"sec-edgar","filing":"0001626199-24-000027","document":"wk-form4_1706573047.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1606243/000162619924000027/wk-form4_1706573047.xml","form_type":"4"}},{"id":1685138,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25347,"kind":"person","name":"Rickey James Paul","position":1,"cik":"0001606243","reported_name":"Rickey James Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to buy)","published_at":"2024-01-05T23:07:28.000Z","date":"2024-01-04","kind":"grant","planned":false,"acquired":true,"shares":78000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"One-fourth (1/4th) of the Shares subject to the Option will vest on January 4, 2025, and one thirty-sixth (1/36th) of the remaining Shares subject to the Option shall vest each month thereafter, subject to the Reporting Person continuing to be a Service Provider through each such date."}],"balance_after":78000,"derivative":{"exercise_price":18.33,"expiration_date":"2034-01-03","underlying":"Common Stock","underlying_shares":78000},"source":{"system":"sec-edgar","filing":"0001626199-24-000023","document":"wk-form4_1704496038.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1606243/000162619924000023/wk-form4_1704496038.xml","form_type":"4"}},{"id":1685137,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25347,"kind":"person","name":"Rickey James Paul","position":1,"cik":"0001606243","reported_name":"Rickey James Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2024-01-05T23:07:28.000Z","date":"2024-01-04","kind":"grant","planned":false,"acquired":true,"shares":31200,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received grant of restricted stock units (\"RSUs\") for no consideration.  One-fourth (1/4th) of the RSUs will vest on January 1, 2025 and the remainder will vest in twelve (12) equal quarterly installments on April 1, 2025  July 1, 2025, October 1, 2025 and on January 1, April 1, July 1, and October 1 of each subsequent year until all RSUs are vested on January 1, 2028, subject to the Reporting Person continuing to be a Service Provider through each such date."}],"balance_after":31200,"source":{"system":"sec-edgar","filing":"0001626199-24-000023","document":"wk-form4_1704496038.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1606243/000162619924000023/wk-form4_1704496038.xml","form_type":"4"}},{"id":1701908,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25347,"kind":"person","name":"Rickey James Paul","position":1,"cik":"0001606243","reported_name":"Rickey James Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to buy)","published_at":"2023-12-22T00:35:53.000Z","date":"2023-12-19","kind":"exercise","planned":true,"acquired":false,"shares":15213,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"100% of the shares underlying the option were fully vested as of April 1, 2021."}],"balance_after":535,"derivative":{"exercise_price":5.02,"expiration_date":"2027-04-11","underlying":"Common Stock","underlying_shares":15213},"source":{"system":"sec-edgar","filing":"0001626199-23-000145","document":"wk-form4_1703205343.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1606243/000162619923000145/wk-form4_1703205343.xml","form_type":"4"}},{"id":1701907,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25347,"kind":"person","name":"Rickey James Paul","position":1,"cik":"0001606243","reported_name":"Rickey James Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2023-12-22T00:35:53.000Z","date":"2023-12-19","kind":"sale","planned":true,"acquired":false,"shares":15213,"price":19.2087,"value":292221.9531,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $19.01 to $19.42. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001626199-23-000145","document":"wk-form4_1703205343.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1606243/000162619923000145/wk-form4_1703205343.xml","form_type":"4"}},{"id":1701906,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25347,"kind":"person","name":"Rickey James Paul","position":1,"cik":"0001606243","reported_name":"Rickey James Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2023-12-22T00:35:53.000Z","date":"2023-12-19","kind":"exercise","planned":true,"acquired":true,"shares":15213,"price":5.02,"value":76369.26,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2023."}],"balance_after":15213,"source":{"system":"sec-edgar","filing":"0001626199-23-000145","document":"wk-form4_1703205343.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1606243/000162619923000145/wk-form4_1703205343.xml","form_type":"4"}},{"id":1706652,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25347,"kind":"person","name":"Rickey James Paul","position":1,"cik":"0001606243","reported_name":"Rickey James Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to buy)","published_at":"2023-12-19T02:20:11.000Z","date":"2023-12-18","kind":"exercise","planned":true,"acquired":false,"shares":1800,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"100% of the shares underlying the option were fully vested as of April 1, 2021."}],"balance_after":15748,"derivative":{"exercise_price":5.02,"expiration_date":"2027-04-11","underlying":"Common Stock","underlying_shares":1800},"source":{"system":"sec-edgar","filing":"0001606243-23-000006","document":"wk-form4_1702952400.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1606243/000160624323000006/wk-form4_1702952400.xml","form_type":"4"}},{"id":1706651,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25347,"kind":"person","name":"Rickey James Paul","position":1,"cik":"0001606243","reported_name":"Rickey James Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to buy)","published_at":"2023-12-19T02:20:11.000Z","date":"2023-12-15","kind":"exercise","planned":true,"acquired":false,"shares":45387,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"100% of the shares underlying the option were fully vested as of April 1, 2021."}],"balance_after":17548,"derivative":{"exercise_price":5.02,"expiration_date":"2027-04-11","underlying":"Common Stock","underlying_shares":45387},"source":{"system":"sec-edgar","filing":"0001606243-23-000006","document":"wk-form4_1702952400.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1606243/000160624323000006/wk-form4_1702952400.xml","form_type":"4"}},{"id":1706650,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25347,"kind":"person","name":"Rickey James Paul","position":1,"cik":"0001606243","reported_name":"Rickey James Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to buy)","published_at":"2023-12-19T02:20:11.000Z","date":"2023-12-14","kind":"exercise","planned":true,"acquired":false,"shares":11600,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"100% of the shares underlying the option were fully vested as of April 1, 2021."}],"balance_after":62935,"derivative":{"exercise_price":5.02,"expiration_date":"2027-04-11","underlying":"Common Stock","underlying_shares":11600},"source":{"system":"sec-edgar","filing":"0001606243-23-000006","document":"wk-form4_1702952400.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1606243/000160624323000006/wk-form4_1702952400.xml","form_type":"4"}},{"id":1706649,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25347,"kind":"person","name":"Rickey James Paul","position":1,"cik":"0001606243","reported_name":"Rickey James Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2023-12-19T02:20:11.000Z","date":"2023-12-18","kind":"sale","planned":true,"acquired":false,"shares":1800,"price":19.0017,"value":34203.06,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This transaction was executed in multiple trades at prices ranging from $19.00 to $19.02. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001606243-23-000006","document":"wk-form4_1702952400.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1606243/000160624323000006/wk-form4_1702952400.xml","form_type":"4"}},{"id":1706648,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25347,"kind":"person","name":"Rickey James Paul","position":1,"cik":"0001606243","reported_name":"Rickey James Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2023-12-19T02:20:11.000Z","date":"2023-12-18","kind":"exercise","planned":true,"acquired":true,"shares":1800,"price":5.02,"value":9036.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2023."}],"balance_after":1800,"source":{"system":"sec-edgar","filing":"0001606243-23-000006","document":"wk-form4_1702952400.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1606243/000160624323000006/wk-form4_1702952400.xml","form_type":"4"}},{"id":1706647,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25347,"kind":"person","name":"Rickey James Paul","position":1,"cik":"0001606243","reported_name":"Rickey James Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2023-12-19T02:20:11.000Z","date":"2023-12-15","kind":"sale","planned":true,"acquired":false,"shares":45387,"price":19.0888,"value":866383.3656,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $19.00 to $19.27. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001606243-23-000006","document":"wk-form4_1702952400.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1606243/000160624323000006/wk-form4_1702952400.xml","form_type":"4"}},{"id":1706646,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25347,"kind":"person","name":"Rickey James Paul","position":1,"cik":"0001606243","reported_name":"Rickey James Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2023-12-19T02:20:11.000Z","date":"2023-12-15","kind":"exercise","planned":true,"acquired":true,"shares":45387,"price":5.02,"value":227842.74,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2023."}],"balance_after":45387,"source":{"system":"sec-edgar","filing":"0001606243-23-000006","document":"wk-form4_1702952400.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1606243/000160624323000006/wk-form4_1702952400.xml","form_type":"4"}},{"id":1706645,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25347,"kind":"person","name":"Rickey James Paul","position":1,"cik":"0001606243","reported_name":"Rickey James Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2023-12-19T02:20:11.000Z","date":"2023-12-14","kind":"sale","planned":true,"acquired":false,"shares":11600,"price":19.0005,"value":220405.8,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $19.00 to $19.07. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001606243-23-000006","document":"wk-form4_1702952400.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1606243/000160624323000006/wk-form4_1702952400.xml","form_type":"4"}},{"id":1706644,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25347,"kind":"person","name":"Rickey James Paul","position":1,"cik":"0001606243","reported_name":"Rickey James Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2023-12-19T02:20:11.000Z","date":"2023-12-14","kind":"exercise","planned":true,"acquired":true,"shares":11600,"price":5.02,"value":58232.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2023."}],"balance_after":11600,"source":{"system":"sec-edgar","filing":"0001606243-23-000006","document":"wk-form4_1702952400.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1606243/000160624323000006/wk-form4_1702952400.xml","form_type":"4"}},{"id":1719770,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25347,"kind":"person","name":"Rickey James Paul","position":1,"cik":"0001606243","reported_name":"Rickey James Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to buy)","published_at":"2023-12-07T00:31:13.000Z","date":"2023-12-06","kind":"exercise","planned":true,"acquired":false,"shares":6446,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of January 23, 2020 (the \"Vesting Commencement Date\") and one forty-eighth (1/48th) of the shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), subject to the Reporting Person continuing to be a Service Provider through each such date."}],"balance_after":19500,"derivative":{"exercise_price":3.23,"expiration_date":"2030-01-22","underlying":"Common Stock","underlying_shares":6446},"source":{"system":"sec-edgar","filing":"0001626199-23-000128","document":"wk-form4_1701909064.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1606243/000162619923000128/wk-form4_1701909064.xml","form_type":"4"}},{"id":1719769,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25347,"kind":"person","name":"Rickey James Paul","position":1,"cik":"0001606243","reported_name":"Rickey James Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to buy)","published_at":"2023-12-07T00:31:13.000Z","date":"2023-12-05","kind":"exercise","planned":true,"acquired":false,"shares":418,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of January 23, 2020 (the \"Vesting Commencement Date\") and one forty-eighth (1/48th) of the shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), subject to the Reporting Person continuing to be a Service Provider through each such date."}],"balance_after":25946,"derivative":{"exercise_price":3.23,"expiration_date":"2030-01-22","underlying":"Common Stock","underlying_shares":418},"source":{"system":"sec-edgar","filing":"0001626199-23-000128","document":"wk-form4_1701909064.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1606243/000162619923000128/wk-form4_1701909064.xml","form_type":"4"}},{"id":1719768,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25347,"kind":"person","name":"Rickey James Paul","position":1,"cik":"0001606243","reported_name":"Rickey James Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to buy)","published_at":"2023-12-07T00:31:13.000Z","date":"2023-12-04","kind":"exercise","planned":true,"acquired":false,"shares":63947,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"Twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of January 23, 2020 (the \"Vesting Commencement Date\") and one forty-eighth (1/48th) of the shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), subject to the Reporting Person continuing to be a Service Provider through each such date."}],"balance_after":26364,"derivative":{"exercise_price":3.23,"expiration_date":"2030-01-22","underlying":"Common Stock","underlying_shares":63947},"source":{"system":"sec-edgar","filing":"0001626199-23-000128","document":"wk-form4_1701909064.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1606243/000162619923000128/wk-form4_1701909064.xml","form_type":"4"}},{"id":1719767,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25347,"kind":"person","name":"Rickey James Paul","position":1,"cik":"0001606243","reported_name":"Rickey James Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2023-12-07T00:31:13.000Z","date":"2023-12-06","kind":"sale","planned":true,"acquired":false,"shares":6446,"price":16.0797,"value":103649.7462,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"This transaction was executed in multiple trades at prices ranging from $16.00 to $16.15.  The price reported above reflects the weighted average sales price.  The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001626199-23-000128","document":"wk-form4_1701909064.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1606243/000162619923000128/wk-form4_1701909064.xml","form_type":"4"}},{"id":1719766,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25347,"kind":"person","name":"Rickey James Paul","position":1,"cik":"0001606243","reported_name":"Rickey James Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2023-12-07T00:31:13.000Z","date":"2023-12-06","kind":"exercise","planned":true,"acquired":true,"shares":6446,"price":3.23,"value":20820.58,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2023."}],"balance_after":6446,"source":{"system":"sec-edgar","filing":"0001626199-23-000128","document":"wk-form4_1701909064.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1606243/000162619923000128/wk-form4_1701909064.xml","form_type":"4"}},{"id":1719765,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25347,"kind":"person","name":"Rickey James Paul","position":1,"cik":"0001606243","reported_name":"Rickey James Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2023-12-07T00:31:13.000Z","date":"2023-12-05","kind":"sale","planned":true,"acquired":false,"shares":418,"price":16.0139,"value":6693.8102,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"This transaction was executed in multiple trades at prices ranging from $16.00 to $16.10.  The price reported above reflects the weighted average sale price.  The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001626199-23-000128","document":"wk-form4_1701909064.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1606243/000162619923000128/wk-form4_1701909064.xml","form_type":"4"}},{"id":1719764,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25347,"kind":"person","name":"Rickey James Paul","position":1,"cik":"0001606243","reported_name":"Rickey James Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2023-12-07T00:31:13.000Z","date":"2023-12-05","kind":"exercise","planned":true,"acquired":true,"shares":418,"price":3.23,"value":1350.14,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2023."}],"balance_after":418,"source":{"system":"sec-edgar","filing":"0001626199-23-000128","document":"wk-form4_1701909064.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1606243/000162619923000128/wk-form4_1701909064.xml","form_type":"4"}},{"id":1719763,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25347,"kind":"person","name":"Rickey James Paul","position":1,"cik":"0001606243","reported_name":"Rickey James Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2023-12-07T00:31:13.000Z","date":"2023-12-04","kind":"sale","planned":true,"acquired":false,"shares":63947,"price":16.0584,"value":1026886.5048,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $16.00 to $16.26.  The price reported above reflects the weighted average sale price.  The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001626199-23-000128","document":"wk-form4_1701909064.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1606243/000162619923000128/wk-form4_1701909064.xml","form_type":"4"}},{"id":1719762,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25347,"kind":"person","name":"Rickey James Paul","position":1,"cik":"0001606243","reported_name":"Rickey James Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2023-12-07T00:31:13.000Z","date":"2023-12-04","kind":"exercise","planned":true,"acquired":true,"shares":63947,"price":3.23,"value":206548.81,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2023."}],"balance_after":63947,"source":{"system":"sec-edgar","filing":"0001626199-23-000128","document":"wk-form4_1701909064.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1606243/000162619923000128/wk-form4_1701909064.xml","form_type":"4"}},{"id":1725060,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25347,"kind":"person","name":"Rickey James Paul","position":1,"cik":"0001606243","reported_name":"Rickey James Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to buy)","published_at":"2023-12-01T22:00:44.000Z","date":"2023-11-30","kind":"exercise","planned":true,"acquired":false,"shares":700,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of January 23, 2020 (the \"Vesting Commencement Date\") and one forty-eighth (1/48th) of the shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), subject to the Reporting Person continuing to be a Service Provider through each such date."}],"balance_after":90311,"derivative":{"exercise_price":3.23,"expiration_date":"2030-01-22","underlying":"Common Stock","underlying_shares":700},"source":{"system":"sec-edgar","filing":"0001606243-23-000003","document":"wk-form4_1701468033.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1606243/000160624323000003/wk-form4_1701468033.xml","form_type":"4"}},{"id":1725059,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25347,"kind":"person","name":"Rickey James Paul","position":1,"cik":"0001606243","reported_name":"Rickey James Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2023-12-01T22:00:44.000Z","date":"2023-11-30","kind":"sale","planned":true,"acquired":false,"shares":700,"price":16,"value":11200.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2023."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001606243-23-000003","document":"wk-form4_1701468033.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1606243/000160624323000003/wk-form4_1701468033.xml","form_type":"4"}},{"id":1725058,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25347,"kind":"person","name":"Rickey James Paul","position":1,"cik":"0001606243","reported_name":"Rickey James Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2023-12-01T22:00:44.000Z","date":"2023-11-30","kind":"exercise","planned":true,"acquired":true,"shares":700,"price":3.23,"value":2261.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2023."}],"balance_after":700,"source":{"system":"sec-edgar","filing":"0001606243-23-000003","document":"wk-form4_1701468033.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1606243/000160624323000003/wk-form4_1701468033.xml","form_type":"4"}},{"id":1746499,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25347,"kind":"person","name":"Rickey James Paul","position":1,"cik":"0001606243","reported_name":"Rickey James Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to buy)","published_at":"2023-11-08T22:20:54.000Z","date":"2023-11-06","kind":"exercise","planned":true,"acquired":false,"shares":10989,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of January 23, 2020 (the \"Vesting Commencement Date\") and one forty-eighth (1/48th) of the shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), subject to the Reporting Person continuing to be a Service Provider through each such date."}],"balance_after":91011,"derivative":{"exercise_price":3.23,"expiration_date":"2030-01-22","underlying":"Common Stock","underlying_shares":10989},"source":{"system":"sec-edgar","filing":"0001626199-23-000119","document":"wk-form4_1699482039.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1606243/000162619923000119/wk-form4_1699482039.xml","form_type":"4"}},{"id":1746498,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25347,"kind":"person","name":"Rickey James Paul","position":1,"cik":"0001606243","reported_name":"Rickey James Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2023-11-08T22:20:54.000Z","date":"2023-11-06","kind":"sale","planned":true,"acquired":false,"shares":18003,"price":16.0281,"value":288553.8843,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"This transaction was executed in multiple trades at prices ranging from $16.00 to $16.19. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":0,"source":{"system":"sec-edgar","filing":"0001626199-23-000119","document":"wk-form4_1699482039.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1606243/000162619923000119/wk-form4_1699482039.xml","form_type":"4"}},{"id":1746497,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25347,"kind":"person","name":"Rickey James Paul","position":1,"cik":"0001606243","reported_name":"Rickey James Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Common Stock","published_at":"2023-11-08T22:20:54.000Z","date":"2023-11-06","kind":"exercise","planned":true,"acquired":true,"shares":10989,"price":3.23,"value":35494.47,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 12, 2023."}],"balance_after":18003,"source":{"system":"sec-edgar","filing":"0001626199-23-000119","document":"wk-form4_1699482039.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1606243/000162619923000119/wk-form4_1699482039.xml","form_type":"4"}},{"id":2061698,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25347,"kind":"person","name":"Rickey James Paul","position":1,"cik":"0001606243","reported_name":"Rickey James Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"See Remarks"}}],"security":"Stock Option (Right to buy)","published_at":"2023-01-06T00:01:56.000Z","date":"2023-01-04","kind":"grant","acquired":true,"shares":109000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One-fourth (1/4th) of the Shares subject to the Option will vest on January 4, 2024, and one thirty-sixth (1/36th) of the remaining Shares subject to the Option shall vest each month thereafter, subject to the Reporting Person continuing to be a service provider through each such date."}],"balance_after":109000,"derivative":{"exercise_price":7.55,"expiration_date":"2033-01-03","underlying":"Common Stock","underlying_shares":109000},"source":{"system":"sec-edgar","filing":"0001626199-23-000022","document":"wf-form4_167296329686813.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1606243/000162619923000022/wf-form4_167296329686813.xml","form_type":"4"}},{"id":2441009,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25347,"kind":"person","name":"Rickey James Paul","position":1,"cik":"0001606243","reported_name":"Rickey James Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP and CFO"}}],"security":"Stock Option (Right to buy)","published_at":"2022-01-06T23:02:14.000Z","date":"2022-01-04","kind":"grant","acquired":true,"shares":112500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"One-fourth (1/4th) of the Shares subject to the Option will vest on the one (1)-year anniversary of January 4, 2022 (the \"Vesting Commencement Date\"), and one thirty-sixth (1/36th) of the remaining Shares subject to the Option shall vest each month thereafter, such that 100% of the Shares subject to the Option will be vested and exercisable as of the four (4)-year anniversary of the Vesting Commencement Date, subject to Optionee continuing to be a Service Provider through each such date."}],"balance_after":112500,"derivative":{"exercise_price":13.3,"expiration_date":"2032-01-03","underlying":"Common Stock","underlying_shares":112500},"source":{"system":"sec-edgar","filing":"0001626199-22-000023","document":"wf-form4_164151011836992.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1606243/000162619922000023/wf-form4_164151011836992.xml","form_type":"4"}},{"id":2447332,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25347,"kind":"person","name":"Rickey James Paul","position":1,"cik":"0001606243","reported_name":"Rickey James Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP and CFO"}}],"security":"Common Stock","published_at":"2022-01-04T22:40:05.000Z","date":"2021-12-31","kind":"sale","acquired":false,"shares":17013,"price":13.9162,"value":236756.3106,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"This transaction was executed in multiple trades at prices ranging from $13.52 to $14.145. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected."}],"balance_after":7014,"source":{"system":"sec-edgar","filing":"0001626199-22-000018","document":"wf-form4_164133597348174.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1606243/000162619922000018/wf-form4_164133597348174.xml","form_type":"4"}},{"id":2914619,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25347,"kind":"person","name":"Rickey James Paul","position":1,"cik":"0001606243","reported_name":"Rickey James Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP and CFO"}}],"security":"Stock Option (Right to buy)","published_at":"2021-01-07T01:04:04.000Z","date":"2021-01-05","kind":"grant","acquired":true,"shares":120000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of January 5, 2021 (the \"Vesting Commencement Date\") and one forty-eighth (1/48th) of the shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), subject to the Reporting Person continuing to be a Service Provider through each such date."}],"balance_after":120000,"derivative":{"exercise_price":13.2,"expiration_date":"2031-01-04","underlying":"Common Stock","underlying_shares":120000},"source":{"system":"sec-edgar","filing":"0001626199-21-000029","document":"wf-form4_160998142987330.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1606243/000162619921000029/wf-form4_160998142987330.xml","form_type":"4"}},{"id":2924927,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25347,"kind":"person","name":"Rickey James Paul","position":1,"cik":"0001606243","reported_name":"Rickey James Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP and CFO"}}],"security":"Common Stock","published_at":"2021-01-05T01:31:42.000Z","date":"2020-12-31","kind":"tax_withholding","acquired":false,"shares":2258,"price":12.6,"value":28450.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units and does not represent a sale by the Reporting Person."}],"balance_after":24027,"source":{"system":"sec-edgar","filing":"0001626199-21-000002","document":"wf-form4_160981028784324.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1606243/000162619921000002/wf-form4_160981028784324.xml","form_type":"4"}},{"id":3094843,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25347,"kind":"person","name":"Rickey James Paul","position":1,"cik":"0001606243","reported_name":"Rickey James Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP and CFO"}}],"security":"Common Stock","published_at":"2020-07-01T23:38:12.000Z","date":"2020-06-30","kind":"tax_withholding","acquired":false,"shares":2258,"price":9.71,"value":21925.18,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares that have been withheld by the Issuer to satisfy its tax withholding and remittance obligations in connection with the net settlement of restricted stock units and does not represent a sale by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Certain of these securities are restricted stock units.  Each restricted stock unit represents a contingent right to receive one share of Common Stock, subject to the applicable vesting schedule and conditions of each restricted stock unit."}],"balance_after":26285,"source":{"system":"sec-edgar","filing":"0000899243-20-018177","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1606243/000089924320018177/doc4.xml","form_type":"4"}},{"id":3301072,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25347,"kind":"person","name":"Rickey James Paul","position":1,"cik":"0001606243","reported_name":"Rickey James Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP and CFO"}}],"security":"Stock Option (right to buy)","published_at":"2020-01-27T23:02:12.000Z","date":"2020-01-23","kind":"grant","acquired":true,"shares":102000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of January 23, 2020 (the \"Vesting Commencement Date\") and one forty-eighth (1/48th) of the shares subject to the Option shall vest each month thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), subject to the Reporting Person continuing to be a Service Provider through each such date."}],"balance_after":102000,"derivative":{"exercise_price":3.23,"expiration_date":"2030-01-22","underlying":"Common Stock","underlying_shares":102000},"source":{"system":"sec-edgar","filing":"0000899243-20-002069","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1606243/000089924320002069/doc4.xml","form_type":"4"}},{"id":3301071,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25347,"kind":"person","name":"Rickey James Paul","position":1,"cik":"0001606243","reported_name":"Rickey James Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP and CFO"}}],"security":"Common Stock","published_at":"2020-01-27T23:02:12.000Z","date":"2020-01-23","kind":"grant","acquired":true,"shares":18543,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Received a grant of restricted stock units (\"RSUs\") pursuant to the 2018 Equity Incentive Plan for no consideration. The RSUs were granted in lieu of a portion of cash incentive compensation achieved pursuant to the terms of the Company's Executive Incentive Compensation Plan.  Fifty percent (50%) of the RSUs will vest on June 30, 2020 and fifty percent (50%) of the RSUs will vest on December 31, 2020, subject to the Reporting Person continuing to be a Service Provider through each such date."}],"balance_after":28543,"source":{"system":"sec-edgar","filing":"0000899243-20-002069","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1606243/000089924320002069/doc4.xml","form_type":"4"}},{"id":3504254,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25347,"kind":"person","name":"Rickey James Paul","position":1,"cik":"0001606243","reported_name":"Rickey James Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP and CFO"}}],"security":"Common Stock","published_at":"2019-06-03T12:00:24.000Z","date":"2019-05-30","kind":"purchase","acquired":true,"shares":10000,"price":4.95,"value":49500.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price.  These shares were purchased in multiple transactions at prices ranging from $4.92 to $5.00, inclusive.  The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote."}],"balance_after":10000,"source":{"system":"sec-edgar","filing":"0000899243-19-015346","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1606243/000089924319015346/doc4.xml","form_type":"4"}},{"id":3667575,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25347,"kind":"person","name":"Rickey James Paul","position":1,"cik":"0001606243","reported_name":"Rickey James Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP and CFO"}}],"security":"Stock Option (right to buy)","published_at":"2019-02-08T21:32:35.000Z","date":"2019-02-06","kind":"grant","acquired":true,"shares":75000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Twenty-five percent (25%) of the shares subject to the Option shall vest on the one (1) year anniversary of February 6, 2019 (the \"Vesting Commencement Date\") and one forty-eighth (1/48th) of the shares subject to the Option shall vest each month  thereafter on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month), subject to the Reporting Person continuing to be a Service Provider through each such date."}],"balance_after":75000,"derivative":{"exercise_price":6.51,"expiration_date":"2029-02-05","underlying":"Common Stock","underlying_shares":75000},"source":{"system":"sec-edgar","filing":"0000899243-19-003038","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1606243/000089924319003038/doc4.xml","form_type":"4"}},{"id":4106604,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25347,"kind":"person","name":"Rickey James Paul","position":1,"cik":"0001606243","reported_name":"Rickey James Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP and CFO"}}],"security":"Stock Option (Right to buy)","published_at":"2018-01-04T22:21:11.000Z","date":"2018-01-02","kind":"grant","acquired":true,"shares":45000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"1/4th of the shares subject to the option become vested and exercisable on January 2, 2019 and 1/36th of the remaining shares subject to the option shall vest monthly thereafter."}],"balance_after":45000,"derivative":{"exercise_price":11.31,"expiration_date":"2028-01-01","underlying":"Common Stock","underlying_shares":45000},"source":{"system":"sec-edgar","filing":"0000899243-18-000496","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1606243/000089924318000496/doc4.xml","form_type":"4"}},{"id":4250696,"issuer":{"id":90802,"kind":"organization","name":"ALPINE IMMUNE SCIENCES, INC.","symbol":"ALPN"},"owners":[{"id":25347,"kind":"person","name":"Rickey James Paul","position":1,"cik":"0001606243","reported_name":"Rickey James Paul","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Senior VP and CFO"}}],"security":"Employee Stock Option (right to buy)","published_at":"2017-07-26T21:11:20.000Z","date":"2017-07-24","kind":"grant","acquired":true,"shares":74535,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Pursuant to that certain Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of April 18, 2017, by and among the Issuer, Nautilus Merger Sub, Inc. and the corporation then known as Alpine Immune Sciences, Inc. (\"Old Alpine\"), each share of Old Alpine common stock was converted into 0.4969 shares of the Issuer's common stock (the \"Exchange Ratio\")."},{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F2","text":"Each option to purchase shares of Old Alpine outstanding and unexercised was assumed by the Issuer pursuant to the Merger Agreement and converted into an option, subject to vesting, to purchase shares of common stock of the Issuer, with the number of shares of the Issuer's common stock underlying such option and the exercise price for such option adjusted to reflect the Exchange Ratio."},{"field":"shares","element":"transactionShares","label":"F1","text":"Pursuant to that certain Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of April 18, 2017, by and among the Issuer, Nautilus Merger Sub, Inc. and the corporation then known as Alpine Immune Sciences, Inc. (\"Old Alpine\"), each share of Old Alpine common stock was converted into 0.4969 shares of the Issuer's common stock (the \"Exchange Ratio\")."},{"field":"shares","element":"transactionShares","label":"F2","text":"Each option to purchase shares of Old Alpine outstanding and unexercised was assumed by the Issuer pursuant to the Merger Agreement and converted into an option, subject to vesting, to purchase shares of common stock of the Issuer, with the number of shares of the Issuer's common stock underlying such option and the exercise price for such option adjusted to reflect the Exchange Ratio."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"This option vests 25% on April 1, 2018, and the remaining 75% vests in 36 substantially equal monthly installments thereafter, subject to the Reporting Person's continued service with the Issuer and certain change of control provisions."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Pursuant to that certain Agreement and Plan of Merger and Reorganization (the \"Merger Agreement\"), dated as of April 18, 2017, by and among the Issuer, Nautilus Merger Sub, Inc. and the corporation then known as Alpine Immune Sciences, Inc. (\"Old Alpine\"), each share of Old Alpine common stock was converted into 0.4969 shares of the Issuer's common stock (the \"Exchange Ratio\")."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F2","text":"Each option to purchase shares of Old Alpine outstanding and unexercised was assumed by the Issuer pursuant to the Merger Agreement and converted into an option, subject to vesting, to purchase shares of common stock of the Issuer, with the number of shares of the Issuer's common stock underlying such option and the exercise price for such option adjusted to reflect the Exchange Ratio."}],"balance_after":74535,"derivative":{"exercise_price":5.02,"expiration_date":"2027-04-11","underlying":"Common Stock","underlying_shares":74535},"source":{"system":"sec-edgar","filing":"0000899243-17-019065","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1606243/000089924317019065/doc4.xml","form_type":"4"}}]}